可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Mancia G. Sympathetic activation in congestive heart failure[J]. Eur Heart J , 1990, 11 ( supplement A ) : 3.
[2] Fracis GS, Goldsmith SR, Xiescke SM , et al. Response of plasma norepinephrine and epinephrine to dynamic exercise in patient with congestive heart failure[J]. Am J cardiol, 1982, 49:1152.
[3] 戴闺柱. 全国心力衰竭诊断与治疗专题研讨会纪要[J]. 中华心血管病杂志, 1995, 23: 95.
[4] Packer M ,Bristow MR, Cohn JN , et al. The effect of carvedilol on morbidity andmotality in patients with chronic heart failure[J]. N Engl J Med , 1996, 334: 1349.
[5] Australia/New Zealand Heart Failure Research Colabo rative Group. Randomized, placebo-controlled trial of carvedilol in patient with congestive heart failure due to ischemic heart disease[J]. Lancet, 1997, 349: 375.
[6] The CIB IS II Scientific committee. Design of the cardiac insufficienty bisoprolol studyII (CIB ISII ) [J]. Fundom Clin Pharmacol, 1997, 11: 138.
[7] Maclellan WR, Schneider MD. Death by design: Programmed cell death in cardiovascular biology and disease [J]. Circ Res,1997, 81: 137.
[8] 司徒镇强, 吴军正. 细胞培养[M]. 西安: 世界图书出版公司,1996. 107- 109.
[9] Cohn JN ,Bristow MR, Kenneth R, et al. Report of the national heart, lung, and blood institute special emphasis panel on heart failure research [J]. Circulation, 1997, 95 (4) : 776.
[10]Haunstetteer A , Izumo S. Apoptosis: Basis mechanism and implications for cardiovascular disease [J]. Circ Res, 1998, 82:1111.
[11]Katz AM. Regression of left ventricular hypertrophy: new hope for dying hearts[J]. Circulation, 1998, 98: 623.